In vitro fertilization cycles stimulated with follitropin delta result in similar embryo development and quality when compared with cycles stimulated with follitropin alfa or follitropin beta.
Embryo quality
follitropin delta
intracytoplasmic sperm injection
in vitro fertilization
pregnancy rates
Journal
F&S reports
ISSN: 2666-3341
Titre abrégé: F S Rep
Pays: United States
ID NLM: 101766618
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
06
08
2020
revised:
02
12
2020
accepted:
10
12
2020
entrez:
5
7
2021
pubmed:
6
7
2021
medline:
6
7
2021
Statut:
epublish
Résumé
To study the impact of follitropin delta for ovarian stimulation on embryo development and quality compared with that of follitropin alfa or beta in in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) cycles. Retrospective cohort study. University-affiliated, hospital-based fertility clinic. A total of 403 IVF/ICSI cycles were conducted from September 1, 2018 to December 31, 2019. Cycles were grouped on the basis of stimulation with follitropin delta vs. follitropin alfa or beta. None. Embryo parameters and clinical pregnancy and implantation rates. Ovarian stimulation using follitropin delta resulted in no statistically significant difference in day 3 embryo quality between the control group and follitropin delta group (median 0.50 vs. 0.54 for good quality embryos and median 0.25 vs. 0.20 for intermediate quality embryos). Although on initial analysis there was a lower proportion of good quality blastocysts in the follitropin delta group than in the control group (0.11 vs. 0.22), this difference was no longer present when day 3 after fertilization vitrification and transfer cycles were excluded (0.26 vs. 0.33 follitropin delta vs. control). The clinical pregnancy rates and clinical implantation rates were similar in both groups in fresh transfer cycles. Stimulation with follitropin delta in IVF/ICSI cycles resulted in similar embryo development and pregnancy rates compared with those of stimulation with follitropin alfa or beta.
Identifiants
pubmed: 34223270
doi: 10.1016/j.xfre.2020.12.002
pii: S2666-3341(20)30128-8
pmc: PMC8244387
doi:
Types de publication
Journal Article
Langues
eng
Pagination
30-35Informations de copyright
© 2020 The Authors.
Références
Fertil Steril. 2000 Jan;73(1):114-6
pubmed: 10632423
Pharmaceuticals (Basel). 2020 Jun 27;13(7):
pubmed: 32605133
Reprod Biomed Online. 2019 Feb;38(2):195-205
pubmed: 30594482
Hum Reprod. 1999 Nov;14(11):2709-15
pubmed: 10548606
Hum Reprod. 2000 Feb;15(2):239-44
pubmed: 10655291
Hum Reprod Update. 2015 Nov-Dec;21(6):698-710
pubmed: 25489055
Fertil Steril. 2015 Apr;103(4):923-930.e1
pubmed: 25624196
Mol Hum Reprod. 2016 Oct;22(10):704-718
pubmed: 27578774
J Clin Pharmacol. 2014 Nov;54(11):1299-307
pubmed: 24800998
Reprod Biomed Online. 2019 Apr;38(4):528-537
pubmed: 30713022
Fertil Steril. 2014 Dec;102(6):1633-40.e5
pubmed: 25256937
Endocr Connect. 2017 Jul;6(5):297-305
pubmed: 28450423
Hum Reprod. 2011 Jun;26(6):1270-83
pubmed: 21502182
Fertil Steril. 2017 Feb;107(2):387-396.e4
pubmed: 27912901
Front Endocrinol (Lausanne). 2019 Jul 03;10:429
pubmed: 31333582
Am J Obstet Gynecol. 2003 Aug;189(2):342-6; discussion 346-7
pubmed: 14520188